Sam Chesterton, Vice President, Business Development, RGA UK
Addressing the UK retirement landscape requires identifying its inevitable transition from defined benefit (DB) to defined contribution (DC) as the primary savings mechanism. This transition places the burden of sufficient pension savings and appropriate retirement decumulation firmly on the individual’s shoulders.
Malik Abbassi-Antoine, Chief Market Development Officer, Europe, Lloyd’s Insurance Company
Jubei Shindo, EVP, Finance, Risk Management, and Accounting Research, Daiichi Life North America, Inc.
Charlotte Halkett, Principal, Milliman
Allison Long, AVP, Social Impact Strategy & Performance, Sun Life
The life and health insurance industry was built on improving people’s health and financial security through collective risk sharing. Consistently delivering on that promise is becoming more complex as populations age, become more diverse, and develop increasingly distinct health and financial needs.
Alexis Gerbeau, CFO, Canada Segment, Manulife
Presented by RGA
Cancer mortality in the United States has declined significantly over the past two decades, reflecting advances in prevention, screening, and treatment. However, new research from RGA reveals a more complex picture beneath these encouraging trends.
Presented by RGA
The future of lifetime income: Why adoption remains low and what comes next to start the description?
The retirement challenge is evolving. For many individuals, the question is no longer whether they can accumulate enough savings for retirement, but whether those savings can provide a reliable income stream throughout an increasingly long retirement.
Presented by Swiss Re
Advancements in targeted therapies, immunotherapy and AI are supporting personalised treatment pathways and improving outcomes for selected cancers.
Presented by RGA
GLP‑1 therapies are emerging as a critical area of focus for both population health and insurance risk. In this roundtable, RGA’s biometric experts examine the latest research and early evidence, unpacking what these therapies could mean in an evolving and uncertain landscape.
Key takeaways:
